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Vaccines are currently available to prevent infection of the genital tract and subsequent disease for some
human papillomavirus (HPV) types, and attempts to develop broadly cross-reactive HPV vaccines are pro-
gressing. A recently developed murine model of cervicovaginal HPV infection examines the mechanisms
by which antibodies prevent infection in vivo.Two HPV vaccines have been approved
for use in many countries and have shown
extraordinary efficacy in preventing infec-
tion and disease caused by the HPV
types included in the respective vaccines
(Mun˜oz et al., 2010). Both vaccines
contain virus-like particles (VLPs) consist-
ing of the major HPV capsid protein, L1,
which elicit neutralizing antibodies that
are predominantly type specific, though
protection to closely related types has
been observed. These neutralizing anti-
bodies have been shown to react with
sequence-specific loops or arms on the
L1 protein, which in vitro prevent binding
to both extracellular matrix and epithelial
cells (Day et al., 2007). One drawback of
the current vaccines is their limited pro-
tection against the plethora of HPV types
that cause HPV-associated neoplasia.
Identification of a cross-reactive epitope
on the minor capsid HPV protein, L2,
has opened the possibility of developing
broadly cross-reactive HPV vaccines
(Jagu et al., 2009). Though evidence has
been accumulating as to how anti-L1
and anti-L2 antibodies block infection of
cells in vitro, there is little information
about how these antibodies function at
the site of infection in the genital tract.
The article by Day et al. (2010) in this issue
of Cell Host & Microbe uses a murine
model of HPV infection of the cervix and
vagina to examine the mechanism by
which antibodies prevent infection.
The cervical vaginal challenge (CVC)
model, developed by the Schiller/Lowy
group at NCI, has helped to define the
molecular processes of HPV infection
(reviewed in Schiller et al., 2010) and
depicted in Figure 1. This model system
uses pseudoviruses composed of the
HPV structural proteins, L1 and L2, which
encapsidate a synthetic plasmid encod-
ing amarker gene. Infection in this contextrefers to delivery of the plasmid to the
nucleus of the cell and expression of the
marker gene. In order to obtain efficient
infection, the genital tract epithelium is
disrupted in ways that may not exactly
parallel natural infection. However, the
great strength of this method is that
reagents have been developed to dissect
each step of the infectious process and to
determine how vaccine-induced anti-
bodies block infection.
To summarize HPV infections briefly,
HPV virions contact the basement mem-
brane through disruptions in the epithelial
layer or at the junction between squa-
mous and columnar epithelium (trans-
formation zone). There, HPVs undergo
conformational changes that expose a
portion of L2 for cleavage by proteases,
rendering the capsids susceptible to
recognition by anti-L2 antibodies. The
conformationally altered HPV capsids can
then interact with as yet undefined recep-
tors on basal epithelial cells for entry and
transfer through intracellular compart-
ments into the nucleus, where transcrip-
tion of viral genes occurs.
Day et al. demonstrate that there are
several mechanisms by which antibodies
elicited by HPV vaccination can prevent
infection. High concentrations of anti-L1
antibodies block binding to the basement
membrane, and, in addition, even low
concentrations of anti-L1 antibodies can
block binding to the epithelial cells. These
findings are very likely relevant to the situ-
ation following natural HPV infections in
women and men and in response to
vaccination. Natural infections result in
delayed and meager immune response,
with levels of L1-specific antibodies being
low and only detectable in approximately
half of women in whom HPV DNA or clin-
ical symptoms are reported (Kirnbauer
et al., 1994; Olsen et al., 1996); responsesCell Host & Microbe 8, Seamong men are even lower (Svare et al.,
1997). In spite of the fact that antibody
levels are often too low to detect, there
are reasons to believe that people are
protected from reinfection with the
same type. First, in a natural history
study, women in whom a particular HPV
sequence variant was detected did not
acquire new HPV sequence variants of
that type, although exposure to new infec-
tions was expected (Sycuro et al., 2008).
Second, in a study of vaccine efficacy,
the HPV 18 vaccine was 98.4% effective,
although 40% of vaccinated women had
undetectable HPV 18 antibodies by the
end of the study (Joura et al., 2008). It is
possible that protection in the absence
of detectable antibodies wasmediated by
cellular responses; however, more likely,
the results of Day et al. suggest that very
low antibody levels can neutralize infec-
tion in vivo.
Experimental data support the idea that
vaccination with a multimeric segment
derived from the amino terminus of L2
proteins can elicit broad cross-neutral-
izing antibodies (Jagu et al., 2009).
The utility of anti-L2 vaccines is as yet
unproven in clinical trials, but a direct
comparison between anti-L1 and anti-L2
vaccines is an attractive feature of the
CVC model. The results of Day et al.
show that anti-L2 antibodies have a
distinct mode of protection from infection,
in that they do not block the initial bind-
ing to the basement membrane but
instead block binding to the receptor on
basal epithelial cells. The demonstration
that L2 antibodies provide protection
from distantly related types is significant,
though how these potential anti-L2
vaccines compare with future multivalent
VLP vaccines remains to be seen. The
CVC in vivo model provides an important
opportunity to compare vaccines directly.ptember 16, 2010 ª2010 Elsevier Inc. 221
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Figure 1. Schematic Representation of HPV Infection and the Mechanisms by Which Anti-L1 and Anti-L2 Vaccines Block Infection
The top panel represents HPV infection. Step 1 involves binding of virus to heparin sulfate proteoglycans (HSPG) on the basement membrane. This results in
a conformational change in the L1 protein, exposing a portion of L2 that is cleaved by a furin-like protease revealing an epitope of L2 (yellow squiggle) shown
in Step 2. The altered capsid can then bind to a receptor on basal cells in Step 3. The middle panel shows that high concentrations of anti-L1 antibodies block
binding to the basement membrane, and lower concentrations of anti-L1 antibodies block binding to basal epithelial cells. The lower panel demonstrates that
anti-L2 antibodies do not affect binding to the basement membrane, the conformational change exposing L2, or cleavage of L2. However, anti-L2 antibodies
block binding of virions with the exposed L2 epitope to basal epithelial cells.
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tection is unknown, and currently there
are no correlates of protection that can
be monitored once antibodies wane.
Efficacy studies lack sufficient follow-up
time to know whether there will be a
need for boosters. As the authors sug-
gest, the CVC model is a potential means
to monitor the neutralization potential
of sera from vaccinees as the levels of
antibodies drop below the detection
threshold of other assays. Although this
model is not amenable to large scale
screens, the principles that have been
discovered here can be used to develop
a new generation of more sensitive
in vitro methods and for the validation of
alternative methods.222 Cell Host & Microbe 8, September 16, 20REFERENCES
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